Margaret Anderson is the executive director of FasterCures, a Washington, D.C.–based center of the Milken Institute, which is driven by a singular goal—to save lives by speeding up and improving the medical research system. FasterCures focuses on spurring cross-sector collaboration, cultivating a culture of innovation, and engaging patients as partners. She is a founding board member and past-president of the Alliance for a Stronger FDA, was a founding member of the NIH National Center for Advancing Translational Sciences Advisory Council, and is a member of the Cures Acceleration Network Review Board, the National Health Council board, the Food and Drug Administration’s Science Board, Science Looking Forward Committee, and the Institute of Medicine’s Forum on Drug Discovery, Development, and Translation. Prior to joining FasterCures in 2004, Anderson was the deputy director and a team leader in the Center on AIDS and Community Health at the Academy for Educational Development, where she led public health projects; program director at the Society for Women’s Health Research; health science analyst at the American Public Health Association, where she managed a programmatic portfolio on HIV/AIDS and other sexually transmitted diseases, infectious diseases, women’s health, and public health infrastructure issues; and analyst and project director at the Congressional Office of Technology Assessment in the Biological Applications Program, where she studied societal and business implications of genetic testing. Anderson holds a bachelor’s degree from the University of Maryland and a master’s degree in science, technology, and public policy from George Washington University.

Recent Posts by Margaret Anderson

Measuring Value Based On What Matters To Patients: A New Value Assessment Framework

Despite the drive toward value-based health care reimbursement and patients’ ever increasing financial stake in their own health care treatment, many traditional value assessment tools fail to consider value from the patient’s perspective.

How Patient Groups Have Begun To Influence The Value And Coverage Debate

Absent from recent high-profile skirmishes on pricing and frameworks was the voice or perspective of patients and patient groups. But that is beginning to change, in an evolution of a broader shift in the role that patients are playing in the research and development enterprise.